Biogen Inc (BIIB)
$220.24-0.57%previous session's close (28 Aug 2026) — awaiting today's first price update
Spriggl Score: Moderate— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Subcutaneous Leqembi launch resolves key catalyst, but Apellis debt caps upgrade at fair P/E.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCL…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $32.2B
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Biogen Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free